Urogen Pharma LTD DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
UroGen Pharma has filed its definitive proxy statement for the 2026 Annual Meeting of Shareholders to be held on June 22, 2026.
NASDAQ
UroGen Pharma Ltd. is convening its 2025 Annual Meeting to vote on key proposals including the election of directors, significant increases in equity compensation for officers and directors, and an expansion of its equity incentive plan, following recent FDA approval for Zusduri and growth in Jelmyto revenue.
NASDAQ
Urogen Pharma Ltd. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission.
NASDAQ
UroGen Pharma has released its proxy statement detailing proposals for its upcoming 2024 Annual Meeting of Shareholders, including director elections, compensation policies, and equity incentive plan amendments.